

Supplementary Information

Figure S1. TFV (top) and TFV-DP (bottom) concentrations in the caudal rabbit vaginal tissue following a single dose of TFV tablet, intact or predissolved, or TFV 1% gel (10 mg TFV each). Data are median + SD ($n = 5$). Dashed line denotes the lower limit of quantitation (100 ng/g).




Figure S2. TFV iliac lymph node concentrations vagina following a single dose of TFV tablet, intact or predissolved, or TFV 1% gel (10 mg TFV each). Data are median + SD ($n = 5$). Dashed line denotes the lower limit of quantitation (20 ng/g).




Figure S3. TFV (top) and TFV-DP (bottom) concentrations in caudal vaginal tissues at 4 and 24 h following a single or 7 daily doses of intact TFV or TFV/FTC tablets. Data are median + SD ($n = 6$). Dashed line denotes the lower limit of quantitation (100 ng/g).




Figure S4. FTC concentrations in caudal vaginal tissues at 4 and 24 h following a single or 7 daily doses of intact FTC or TFV/FTC tablets. Data are median + SD ($n = 6$).




Figure S5. TFV concentrations in iliac lymph nodal tissues at 4 and 24 h following a single or 7 daily doses of intact TFV or TFV/FTC tablets. Data are median + SD ($n = 6$).

